6.
Ma X, Dai Z, Sun K, Zhang Y, Chen J, Yang Y
. Intestinal Epithelial Cell Endoplasmic Reticulum Stress and Inflammatory Bowel Disease Pathogenesis: An Update Review. Front Immunol. 2017; 8:1271.
PMC: 5660968.
DOI: 10.3389/fimmu.2017.01271.
View
7.
Hillary R, Fitzgerald U
. A lifetime of stress: ATF6 in development and homeostasis. J Biomed Sci. 2018; 25(1):48.
PMC: 5968583.
DOI: 10.1186/s12929-018-0453-1.
View
8.
Woo C, Cui D, Arellano J, Dorweiler B, Harding H, Fitzgerald K
. Adaptive suppression of the ATF4-CHOP branch of the unfolded protein response by toll-like receptor signalling. Nat Cell Biol. 2009; 11(12):1473-80.
PMC: 2787632.
DOI: 10.1038/ncb1996.
View
9.
Eugene S, Reddy V, Trinath J
. Endoplasmic Reticulum Stress and Intestinal Inflammation: A Perilous Union. Front Immunol. 2020; 11:543022.
PMC: 7723926.
DOI: 10.3389/fimmu.2020.543022.
View
10.
Kong L, Chen S, Huang S, Zheng A, Gao S, Ye J
. Challenges and opportunities in inflammatory bowel disease: from current therapeutic strategies to organoid-based models. Inflamm Res. 2024; 73(4):541-562.
DOI: 10.1007/s00011-024-01854-z.
View
11.
Rab A, Bartoszewski R, Jurkuvenaite A, Wakefield J, Collawn J, Bebok Z
. Endoplasmic reticulum stress and the unfolded protein response regulate genomic cystic fibrosis transmembrane conductance regulator expression. Am J Physiol Cell Physiol. 2006; 292(2):C756-66.
DOI: 10.1152/ajpcell.00391.2006.
View
12.
Woodward A, Di Zazzo A, Bonini S, Argueso P
. Endoplasmic reticulum stress promotes inflammation-mediated proteolytic activity at the ocular surface. Sci Rep. 2020; 10(1):2216.
PMC: 7010695.
DOI: 10.1038/s41598-020-59237-3.
View
13.
de Bruyn M, Vandooren J, Ugarte-Berzal E, Arijs I, Vermeire S, Opdenakker G
. The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases. Crit Rev Biochem Mol Biol. 2016; 51(5):295-358.
DOI: 10.1080/10409238.2016.1199535.
View
14.
Rieder F, Brenmoehl J, Leeb S, Scholmerich J, Rogler G
. Wound healing and fibrosis in intestinal disease. Gut. 2006; 56(1):130-9.
PMC: 1856649.
DOI: 10.1136/gut.2006.090456.
View
15.
Gisbert J, Chaparro M
. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohns Colitis. 2019; 14(5):694-709.
DOI: 10.1093/ecco-jcc/jjz195.
View
16.
Thakur S, Ankita , Dash S, Verma R, Kaur C, Kumar R
. Understanding CFTR Functionality: A Comprehensive Review of Tests and Modulator Therapy in Cystic Fibrosis. Cell Biochem Biophys. 2023; 82(1):15-34.
DOI: 10.1007/s12013-023-01200-w.
View
17.
Schreiber S, Siegel C, Friedenberg K, Younes Z, Seidler U, Bhandari B
. A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease. J Crohns Colitis. 2018; 12(9):1014-1020.
PMC: 6113705.
DOI: 10.1093/ecco-jcc/jjy070.
View
18.
Saptarshi N, Porter L, Paraoan L
. PERK/EIF2AK3 integrates endoplasmic reticulum stress-induced apoptosis, oxidative stress and autophagy responses in immortalised retinal pigment epithelial cells. Sci Rep. 2022; 12(1):13324.
PMC: 9349321.
DOI: 10.1038/s41598-022-16909-6.
View
19.
Martinon F, Chen X, Lee A, Glimcher L
. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat Immunol. 2010; 11(5):411-8.
PMC: 3113706.
DOI: 10.1038/ni.1857.
View
20.
Farrell R, Kelleher D
. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 2003; 178(3):339-46.
DOI: 10.1677/joe.0.1780339.
View